Canthaxanthin Mitigates Cardiovascular Senescence in Vitro and in Vivo
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2902070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Zhefeng Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Center for Biotherapy, Central Laboratory, Zhongshan Hospital (Xiamen), Fudan University, 361015 Xiamen, Fujian, China. Hauptthemen laut MEDLINE: Aging, Premature, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Top Talent of SZTU.
Abstract (Originalsprache)
Background
The number of older people in the world is increasing year by year; studies have shown that more than 90% of cardiovascular disease occurs in the older people population, indicating that aging is one of the major risks involved in the development of cardiovascular disease. Therefore, retarding the development of cardiac aging is an important strategy to prevent aging-related cardiovascular diseases.
Methods
In the current study, we examined the anti-cardiovascular aging potential of canthaxanthin in vitro and in vivo experiments. For this, a model of cardiomyocyte senescence induced by D-galactose was established, which was used to investigate the canthaxanthin’s effect on cardiac premature aging.
Results
We found that canthaxanthin obviously mitigated the cardiomyocyte senescence in vitro. Further mechanistic studies revealed that canthaxanthin seems to alleviate cardiomyocyte senescence by regulating the autophagy process. Furthermore, the effects of canthaxanthin on cardiovascular senescence were further evaluated. We also observed that canthaxanthin mitigated cardiac aging and fibrosis in the aged mice model.
Conclusions
To sum up, the current work showed that canthaxanthin could obviously alleviate cardiac premature aging, indicating that canthaxanthin could be used as a biologically active molecule for the treatment of cardiac aging and fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Center for Biotherapy, Central Laboratory, Zhongshan Hospital (Xiamen), Fudan University, 361015 Xiamen, Fujian, China.
- Department of Cardiology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), 518020 Shenzhen, Guangdong, China.
- Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, 510632 Guangzhou, Guangdong, China.
- Xiamen Clinical Research Center for Cancer Therapy, 361015 Xiamen, Fujian, China.
- College of Pharmacy, Shenzhen Technology University, 518118 Shenzhen, Guangdong, China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Top Talent of SZTU
Zitieren
APA
Wang, Z., Liu, W., Zhang, M., Yan, J., Fei, J., Zhang, K., & Dong, S. (2024). Canthaxanthin Mitigates Cardiovascular Senescence in Vitro and in Vivo. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2902070
Vancouver
Wang Z, Liu W, Zhang M, Yan J, Fei J, Zhang K, et al. Canthaxanthin Mitigates Cardiovascular Senescence in Vitro and in Vivo. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2902070
BibTeX
@article{Wang2024,
author = {Wang, Zhefeng and Liu, Wenxing and Zhang, Min and Yan, Jianlong and Fei, Jia and Zhang, Keda and Dong, Shaohong},
title = {Canthaxanthin Mitigates Cardiovascular Senescence in Vitro and in Vivo},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2902070}
}
EUVIMED